{"entity":{"id":"nct06584227","kind":"trial","name":"Adebrelimab and Chidamide for Pancreatic Cancer","aka":["ACPC"],"tldr":"A phase 2 trial of adebrelimab and gemcitabine in pancreatic cancer, run by Liu Xiufeng, now recruiting.","summary":"Adebrelimab and Chidamide for Pancreatic Cancer is a phase 2, interventional study registered as NCT06584227 by Liu Xiufeng, with a registry enrolment figure of 45 participants, started 2024-09-10 and due to reach its primary completion in 2026-07-10. Interventions recorded: Adebrelimab and Chidamide Combined with Gemcitabine and S1. Conditions listed: Pancreatic Cancer, Adult. Primary outcome: Progression free survival. Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed pancreatic cancer (originating from the ductal epithelium of the pancreas) with clinically documented unresectable locally advanced or metastatic pancreatic cancer (stage III/IV according to the TNM stage of AJCC 8 pancreatic cancer);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06584227","url":"https://clinicaltrials.gov/study/NCT06584227"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["adebrelimab","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06584227","phase":"2","setting":"A Single-Arm, Multicenter, Open, Phase II Clinical Study of Adebrelimab and Chidamide in Combination With Gemcitabine and S1 for the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"Liu Xiufeng","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06584227/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}